

bluebird bio, Inc.  
Form 8-K  
July 16, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): July 16, 2014**

**bluebird bio, Inc.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State or other jurisdiction of**  
**incorporation)**

**001-35966**  
**(Commission File Number)**

**13-3680878**  
**(I.R.S. Employer**  
**Identification No.)**

**150 Second Street**

**Cambridge, MA**  
**(Address of principal executive offices)**

**02141**  
**(Zip Code)**

Registrant's telephone number, including area code **(339) 499-9300**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On July 16, 2014, the board of directors (the Board) of bluebird bio, Inc. (the Company), upon the recommendation of the Company's corporate governance and nominating committee, appointed Mr. Mark Vachon to the Board and its Audit Committee. In connection with his appointment, on July 16, 2014, the Company granted Mr. Vachon a stock option to purchase 20,000 shares of common stock with an exercise price of \$30.47, the closing price of the Company's common stock on the Nasdaq Global Select Market on July 16, 2014.

Mr. Vachon is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Vachon and any other persons pursuant to which he was selected as a director.

**Item 7.01 Regulation FD Disclosure**

On July 16, 2014, the Company issued a press release announcing Mr. Vachon's appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued by bluebird bio, Inc. on July 16, 2014, furnished herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 16, 2014

**bluebird bio, Inc.**

By: /s/ Jason F. Cole  
Jason F. Cole

Senior Vice President and General Counsel

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued by bluebird bio, Inc. on July 16, 2014, furnished herewith.